¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå ¿¹Ãø(-2031³â) : Áö¿ªº° ºÐ¼®- Á¦Ç°º°, Çüź°, À¯Çüº°, À¯Åëä³Îº°
Asia Pacific Dry Eye Products Market Forecast to 2031 - Regional Analysis - by Product, Dosage Form, Type, and Distribution Channel
»óǰÄÚµå : 1666251
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 117 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,450 £Ü 4,991,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 4,450 £Ü 6,438,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,450 £Ü 7,885,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀåÀº 2023³â¿¡ 11¾ï 146¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2031³â±îÁö´Â 16¾ï 4,184¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2023³âºÎÅÍ 2031³â±îÁöÀÇ CAGRÀº 5.1%·Î ÃßÁ¤µË´Ï´Ù.

´« °ü¸® ÀÎ½Ä Á¦°í¸¦ À§ÇÑ ³ë·ÂÀÇ Áõ°¡·Î ¾Æ½Ã¾ÆÅÂÆò¾ç ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå È®´ë

ÃÖ±Ù ¸î ³â µ¿¾È ¾È±¸ Áúȯ¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀÌ°í »ç¶÷µéÀ» ±³À°Çϱâ À§ÇÑ ´Ù¾çÇÑ ³ë·ÂÀÌ ÁøÇàµÇ¾î ȯÀÚµéÀÌ ÀûÀýÇÑ ¾à¹°°ú Ä¡·á¹ýÀ» ÀÌ¿ëÇÒ ¼ö ÀÖµµ·Ï À¯µµÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ABP(Avoidable Blindness Program : ȸÇÇ °¡´ÉÇÑ ½Ç¸í ÇÁ·Î±×·¥)ÀÇ ÀÏȯÀ¸·Î, Novartis´Â »çÇ϶ó À̳²ÀÇ ¾ÆÇÁ¸®Ä«¿Í µ¿³²¾Æ½Ã¾Æ Àü¿ªÀÇ ÆÄÆ®³Ê¿Í Çù·ÂÇÏ¿© 2022³â¿¡ ÀÌ È¸»çÀÇ ¾ÆÀÌÄɾî Á¦Ç°À» ÀÌ¿ëÇÒ ¼ö ÀÖµµ·Ï Çß½À´Ï´Ù. ABP´Â ¿¹¹æ °¡´ÉÇÑ ½Ç¸íÀÇ »ó´ç ºÎºÐÀ» Â÷ÁöÇÏ´Â ³ì³»Àå ¹× ¸Á¸· ÁúȯÀ¸·Î ÀÎÇÑ Áߵ¿¡¼­ ÁßÁõ ½Ã·Â ¼Õ»ó¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.

±¹Á¦½Ç¸í¿¹¹æ±â±¸(IAPB)´Â ´« °Ç°­ÀÇ »çȸ°æÁ¦Àû Á߿伺¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̱â À§ÇØ 2022³â¿¡ 'Love Your Eyes'¶ó´Â ±Û·Î¹ú Ä·ÆäÀÎÀ» ½ÃÀÛÇß½À´Ï´Ù. ÀÌ Ä·ÆäÀÎÀº °¢±¹ Á¤ºÎ¿Í ±Û·Î¹ú ±â°ü¿¡ ´« °Ç°­À» Áö¿øÇÒ °ÍÀ» Ã˱¸ÇÕ´Ï´Ù. IAPB´Â Àεµ¿Í Àü ¼¼°è¿¡¼­ Á¢±Ù °¡´ÉÇϰí ÀÌ¿ë °¡´ÉÇϸç Àú·ÅÇÑ ¾È°ú Ä¡·á¸¦ ½Å¼ÓÇÏ°Ô Á¦°øÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃá ÇÁ·Î±×·¥°ú ³ë·ÂÀ» °­Á¶ÇÕ´Ï´Ù. 'Love Your Eyes' ÇÁ·Î±×·¥Àº ¶ÇÇÑ 2030³â±îÁö ¾È°ú Ä¡·á¸¦ Á¢±Ù¼º, °¡¿ë¼º, °æÁ¦¼º ÀÖ°Ô Á¦°øÇϱâ À§ÇÑ ±ÔÁ¦ º¯°æ°ú ÀÚ±Ý Áö¿øÀ» Ã˱¸Çϰí ÀÖ½À´Ï´Ù.

2022³â 12¿ù, Research to Prevent Blindness´Â ¹Ì±¹ À¯Å¸ ´ëÇÐÀÇ Á¸ A. ¸ð¶õ ¾È°ú ¼¾Å͸¦ ¼±ÅÃÇÏ°í ¾È°ú ¿¬±¸¸¦ Áö¿øÇϱâ À§ÇØ ¿¬°£ 115,000´Þ·¯¸¦ ¹«Á¦ÇÑÀ¸·Î Á¶¼ºÇß½À´Ï´Ù. ¹Ì±¹ ±¹¸³º¸°Ç¿ø(NIH)Àº Àεµ ¾Æ¶óºóµå ¾È°úº´¿ø°ú ÄÌ·Î±× ¾È°ú¼¾ÅÍ °£ÀÇ ÆÄÆ®³Ê½ÊÀ» Áö¿øÇÏ¿© ¾È°ú Àü¹®°¡¸¦ À§ÇÑ ÀÓ»ó ¿¬±¸ ±³À° ÇÁ·Î±×·¥À» °³¹ßÇß½À´Ï´Ù. ÀÌ ÀÏȯÀ¸·Î NIH´Â ¹Ì±¹ ¾Ø¾Æ¹ö¿¡¼­ ÁøÇàµÇ´Â ±³À° ÇÁ·Î±×·¥À» Áö¿øÇϱâ À§ÇØ 110¸¸ ´Þ·¯¸¦ Áö¿øÇßÀ¸¸ç, Âü°¡Àڵ鿡°Ô Á¾ÀÚ ÀÚ±ÝÀ» Á¦°øÇß½À´Ï´Ù. ¶ÇÇÑ Àεµ-¹Ì±¹ °øµ¿ ½Ã·Â ¿¬±¸ ÇÁ·Î±×·¥ 2020Àº ½Ç¸í ½Ã°¢ Àå¾Ö, ¾ÈÁúȯ ¹× °ü·Ã ÇÕº´ÁõÀ» ÀÌÇØ, ¿¹¹æ, Ä¡·áÇϱâ À§ÇÑ °úÇÐ ±â¼ú ¹ßÀü¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù. Àεµ »ý¸í°øÇÐºÎ¿Í ¹Ì±¹ ±¹¸³¾È¿¬±¸¼Ò°¡ ÀÌ ¿¬±¸ ÇÁ·Î±×·¥¿¡ ÀÚ±ÝÀ» Áö¿øÇß½À´Ï´Ù.

µû¶ó¼­ ¾È±¸ °ü¸® ¿¬±¸¿¡ ´ëÇÑ ÀÚ±ÝÀÌ Áõ°¡ÇÏ°í ¾È±¸ °ü¸®¿¡ ´ëÇÑ ÀνÄÀ» È®»êÇϱâ À§ÇÑ ³ë·ÂÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÇâÈÄ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå¿¡¼­ »õ·Î¿î ±âȸ°¡ âÃâµÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå °³¿ä

¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀåÀº Áß±¹, Àεµ, ÀϺ», Çѱ¹, È£ÁÖ ¹× ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç Áö¿ªÀ¸·Î ¼¼ºÐÈ­µË´Ï´Ù. ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î º¸ÀÌ´Â ¿äÀÎÀ¸·Î´Â Àå½Ã°£ ÄÄÇ»ÅÍ »ç¿ëÀ¸·Î ÀÎÇÑ ÀþÀº ÃþÀÇ ¾È±¸°ÇÁ¶Áõ ¹ßº´·ü Áõ°¡, ¾È±¸ °Ç°­¿¡ ´ëÇÑ Á¤ºÎ Áö¿ø Áõ°¡, ¾È°ú ¼Ö·ç¼ÇÀÇ Áö¼ÓÀûÀÎ °³¹ß µîÀÌ ÀÖ½À´Ï´Ù. NIH¿¡ µû¸£¸é Áß±¹¿¡¼­´Â ¸Å³â 20-30%ÀÇ »ç¶÷µéÀÌ ¾È±¸°ÇÁ¶Áõ Áø´ÜÀ» ¹Þ°í ÀÖ½À´Ï´Ù. Áß±¹ÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀåÀº ±¹³»¿Ü Á¦¾àȸ»ç°¡ ¸ðµÎ ÁøÃâÇØ ÀÖ¾î °æÀïÀÌ Ä¡¿­ÇÕ´Ï´Ù. Novaliq´Â ¾È±¸°ÇÁ¶Áõ Ä¡·á¸¦ À§ÇÑ NOV03ÀÇ Á¦Á¶, °³¹ß ¹× »ó¿ëÈ­¸¦ À§ÇØ Àå¾¥ Çë·çÀÌ Á¦¾à°ú Àü·«Àû Çù·Â °ü°è¸¦ ±¸ÃàÇß½À´Ï´Ù. 2021³â 12¿ù, Hengrui´Â SHR8058(NOV03)ÀÇ Áß¿äÇÑ ÀÓ»ó 3»ó ½ÃÇè¿¡¼­ ±àÁ¤ÀûÀÎ °á°ú¸¦ ¾ò¾úÀ¸¸ç, ÀÌ ½ÃÇèÀº Áß±¹ Àü¿ª 17°³ ±â°ü¿¡¼­ ½Ç½ÃµÇ¾ú½À´Ï´Ù. Áß±¹ ȸ»ç´Â ÀÌ Á¦Ç°À» Áß±¹°ú µ¿³²¾Æ½Ã¾Æ Àü¿ª¿¡ À¯ÅëÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå ¼öÀͰú ¿¹Ãø(-2031³â)

¾Æ½Ã¾ÆÅÂÆò¾ç ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå ¼¼ºÐÈ­

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀåÀº Á¦Ç°, Á¦Çü, Á¦Ç° À¯Çü, À¯Åë ä³Î ¹× ±¹°¡º°·Î ºÐ·ùµË´Ï´Ù.

Á¦Ç°¿¡ µû¶ó ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀåÀº Àΰø ´«¹°, Ç׿°ÁõÁ¦, ´©°ø Ç÷¯±×, ºÐºñ ÃËÁøÁ¦, °æ±¸ ¿À¸Þ°¡ º¸ÃæÁ¦ µîÀ¸·Î ¼¼ºÐÈ­µË´Ï´Ù. Àΰø ´«¹° ºÎ¹®Àº 2023³â ¾Æ½Ã¾ÆÅÂÆò¾ç ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¶ÇÇÑ Ç׿°ÁõÁ¦ ºÎ¹®Àº »çÀÌŬ·Î½ºÆ÷¸°, ÄÚ¸£Æ¼ÄÚ ½ºÅ×·ÎÀÌµå ¹× ±âŸ·Î ¼¼ºÐÈ­µË´Ï´Ù. ¶ÇÇÑ ´©°ø Ç÷¯±× ºÎ¹®Àº ¿ëÇØ¼º ¹× Á¦°Å °¡´ÉÀ¸·Î ¼¼ºÐÈ­µË´Ï´Ù.

Á¦Çüº°·Î, ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀåÀº Á¡¾È¾×, Á©, ĸ½¶ ¹× Á¤Á¦ µîÀ¸·Î ¼¼ºÐÈ­µË´Ï´Ù. Á¡¾ÈÁ¦ ºÎ¹®Àº 2023 ³â ¾Æ½Ã¾ÆÅÂÆò¾ç ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

Á¦Ç° À¯Çüº°·Î, ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀåÀº ÀϹÝÀǾàǰ°ú 󹿾àÀ¸·Î ³ª´¹´Ï´Ù. OTC ºÎ¹®Àº 2023 ³â ¾Æ½Ã¾ÆÅÂÆò¾ç ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå¿¡¼­ ´õ Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

À¯Åë ä³Î¿¡ µû¶ó ¾Æ½Ã¾ÆÅÂÆò¾ç ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀåÀº ¼Ò¸Å ¾à±¹, º´¿ø ¾à±¹ ¹× ¿Â¶óÀÎ ¾à±¹À¸·Î ºÐ·ùµË´Ï´Ù. ¼Ò¸Å ¾à±¹ ºÎ¹®ÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀåÀº Áß±¹, ÀϺ», Àεµ, È£ÁÖ, Çѱ¹ ¹× ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ºÐ·ùµË´Ï´Ù. 2023³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå Á¡À¯À²Àº Áß±¹ÀÌ µ¶Á¡Çß½À´Ï´Ù.

Santen Pharmaceutical Co Ltd¡¢Johnson &Johnson¡¢OASIS Medical¡¢URSAPHARM Arzneimittel GmbH¡¢Rohto Pharmaceutical Co Ltd¡¢OCuSOFT Inc¡¢Bausch Health Companies Inc¡¢AbbVie Inc¡¢Prestige Consumer Healthcare Inc¡¢Farmigea SpA¡¢Alcon AG´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾È±¸ °ÇÁ¶Áõ Á¦Ç° ½ÃÀåÀ» ÁÖµµÇÏ´Â ±â¾÷µéÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

Á¦5Àå ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå : ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå ºÐ¼®

Á¦6Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå ºÐ¼® : Á¦Ç°º°

Á¦7Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå ºÐ¼® : Á¦Çüº°

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå ºÐ¼® : Á¦Ç° À¯Çüº°

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå ºÐ¼® : À¯Åëä³Îº°

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾È±¸°ÇÁ¶Áõ Á¦Ç° ½ÃÀå : ±¹°¡º° ºÐ¼®

Á¦11Àå ¾÷°è Á¤¼¼

Á¦12Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦13Àå ºÎ·Ï

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Asia Pacific dry eye products market was valued at US$ 1,101.46 million in 2023 and is expected to reach US$ 1,641.84 million by 2031; it is estimated to register a CAGR of 5.1% from 2023 to 2031.

Increasing Initiatives for Eye Care Awareness Boost Asia Pacific Dry Eye Products Market

In recent years, various initiatives have been taken to create awareness and educate people regarding eye diseases, prompting patients to access suitable medications and treatments. For instance, as a part of the Avoidable Blindness Program (ABP) (launched in 2021), Novartis worked with its partners across Sub-Saharan Africa and Southeast Asia to access to its eye care products in 2022. ABP focuses on moderate to severe vision damage caused by glaucoma and retinal conditions that are responsible for a large proportion of preventable blindness.

The International Agency for the Prevention of Blindness (IAPB) launched the global campaign named "Love Your Eyes" in 2022 to raise awareness of the socioeconomic importance of eye health. The campaign calls upon governments and global institutions to support eye health. The IAPB emphasizes programs and initiatives in India and the world, which promptly focus on offering accessible, available, and affordable eye care. The "Love Your Eyes" program also calls for regulation changes and funding to make eye care accessible, available, and affordable by 2030.

In December 2022, Research to Prevent Blindness selected the John A. Moran Eye Center at the University of Utah for the unlimited annual grant of US$ 115,000 to support eye research. As of December 2021, the National Institutes of Health (NIH) supported a partnership between Aravind Eye Hospital (India) and Kellogg Eye Center to develop a clinical research training program for eyecare professionals. As a part of this initiative, the NIH awarded US$ 1.1 million to support training programs in Ann Arbor (US) and offered seed funding for the participants. In addition, the India-US Collaborative Vision Research Program 2020 focuses on advancing science and technology to understand, prevent, and treat blinding visual disorders, eye diseases, and associated complications. The Indian Department of Biotechnology and the US National Eye Institute funded this research program.

Thus, increasing funds for eyecare research and rising initiatives to spread awareness about eye care are likely to create new opportunities in the dry eye product market in the coming years.

Asia Pacific Dry Eye Products Market Overview

The Asia Pacific dry eye products market is segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. The factors that are likely to contribute to the market growth in this region include the increasing incidence of DED among young people due to prolonged usage of computers, growing government support for eye health, and ongoing developments in ophthalmic solutions. According to NIH, in China, ~20-30% of people are diagnosed with dry eye conditions every year. The dry eye products market in China is quite competitive, with the presence of both domestic and international pharmaceutical companies. Novaliq has established a strategic cooperation with Jiangsu Hengrui Pharmaceuticals to manufacture, develop, and commercialize NOV03 for the treatment of dry eye disease. In December 2021, Hengrui obtained positive outcomes from the critical Phase 3 clinical trial of SHR8058 (NOV03) for the treatment of dry eye disease linked with meibomian gland dysfunction; the trial was conducted at 17 sites across China. The Chinese firm is expected to distribute these products across China and Southeast Asia.

Asia Pacific Dry Eye Products Market Revenue and Forecast to 2031 (US$ Million)

Asia Pacific Dry Eye Products Market Segmentation

The Asia Pacific dry eye products market is categorized into product, dosage form, type, distribution channel, and country.

Based on product, the Asia Pacific dry eye products market is segmented into artificial tears, anti-inflammatory drugs, punctal plugs, secretagogues, oral omega supplements, and others. The artificial tears segment held the largest Asia Pacific dry eye products market share in 2023. Furthermore, the anti-inflammatory drugs segment is subcategorized into cyclosporine, corticosteroid, and others. Additionally, the punctal plugs segment is subsegmented into dissolvable and removable.

In terms of dosage form, the Asia Pacific dry eye products market is segmented into eye drops, gel, capsules and tablets, and others. The eye drops segment held the largest Asia Pacific dry eye products market share in 2023.

By type, the Asia Pacific dry eye products market is bifurcated into OTC and prescription. The OTC segment held a larger Asia Pacific dry eye products market share in 2023.

Based on distribution channel, the Asia Pacific dry eye products market is categorized into retail pharmacy, hospital pharmacy, and online pharmacy. The retail pharmacy segment held the largest Asia Pacific dry eye products market share in 2023.

Based on country, the Asia Pacific dry eye products market is categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific dry eye products market share in 2023.

Santen Pharmaceutical Co Ltd, Johnson & Johnson, OASIS Medical, URSAPHARM Arzneimittel GmbH, Rohto Pharmaceutical Co Ltd, OCuSOFT Inc, Bausch Health Companies Inc, AbbVie Inc, Prestige Consumer Healthcare Inc, Farmigea SpA, and Alcon AG are some of the leading companies operating in the Asia Pacific dry eye products market.

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Asia Pacific Dry Eye Products Market - Key Market Dynamics

5. Dry Eye Products Market - Asia Pacific Market Analysis

6. Asia Pacific Dry Eye Products Market Analysis - by Product

7. Asia Pacific Dry Eye Products Market Analysis - by Dosage Form

8. Asia Pacific Dry Eye Products Market Analysis - by Type

9. Asia Pacific Dry Eye Products Market Analysis - by Distribution Channel

10. Asia Pacific Dry Eye Products Market - Country Analysis

11. Industry Landscape

12. Company Profiles

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â